B Stollenwerk1, T Bartmus, F Klug, S Stock, D Müller. 1. Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Health Economics and Health Care Management, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany, bjoern.stollenwerk@helmholtz-muenchen.de.
Abstract
UNLABELLED: In this study, we determined the cost-effectiveness of hip protector use compared with no hip protector on a geriatric ward in Germany. From both the societal and the statutory health insurance (SHI) perspectives, the cost-effectiveness ratios for the provision of hip protectors were below <euro>12,000/quality-adjusted life year (QALY) even if unrelated costs in added life years were included. INTRODUCTION: The aim of this study is to determine the cost-effectiveness of the provision of hip protectors compared with no hip protectors on a geriatric ward in Germany. METHODS: A lifetime decision-analytic Markov model was developed. Costs were measured from the societal and from the statutory health insurance (SHI) perspectives and comprised direct medical, non-medical and unrelated costs in additional life years gained. Health outcomes were measured in terms of quality-adjusted life years (QALYs). To reflect several levels of uncertainty, first- and second-order Monte Carlo simulation (MCS) approaches were applied. RESULTS: Hip protector use compared with no hip protector results in savings (costs, -5.1/QALYs, 0.003) for the societal perspective. For the SHI perspective, the incremental cost-effectiveness ratio was <euro>4416 <euro>/QALY (costs, +13.4). If unrelated costs in life years gained were included, the cost-effectiveness ratio increases to <euro>9794/QALY for the societal perspective and to <euro>11,426/QALY for the SHI perspective. In the MCS, for the societal perspective without unrelated costs, 47 % of simulations indicated hip protectors to be cost saving (i.e. lower costs and higher effects). CONCLUSION: Although the gain in QALYs due to the provision of providing hip protectors to patients on geriatric wards is small, all scenarios showed acceptable cost-effectiveness ratios or even savings.
UNLABELLED: In this study, we determined the cost-effectiveness of hip protector use compared with no hip protector on a geriatric ward in Germany. From both the societal and the statutory health insurance (SHI) perspectives, the cost-effectiveness ratios for the provision of hip protectors were below <euro>12,000/quality-adjusted life year (QALY) even if unrelated costs in added life years were included. INTRODUCTION: The aim of this study is to determine the cost-effectiveness of the provision of hip protectors compared with no hip protectors on a geriatric ward in Germany. METHODS: A lifetime decision-analytic Markov model was developed. Costs were measured from the societal and from the statutory health insurance (SHI) perspectives and comprised direct medical, non-medical and unrelated costs in additional life years gained. Health outcomes were measured in terms of quality-adjusted life years (QALYs). To reflect several levels of uncertainty, first- and second-order Monte Carlo simulation (MCS) approaches were applied. RESULTS: Hip protector use compared with no hip protector results in savings (costs, -5.1/QALYs, 0.003) for the societal perspective. For the SHI perspective, the incremental cost-effectiveness ratio was <euro>4416 <euro>/QALY (costs, +13.4). If unrelated costs in life years gained were included, the cost-effectiveness ratio increases to <euro>9794/QALY for the societal perspective and to <euro>11,426/QALY for the SHI perspective. In the MCS, for the societal perspective without unrelated costs, 47 % of simulations indicated hip protectors to be cost saving (i.e. lower costs and higher effects). CONCLUSION: Although the gain in QALYs due to the provision of providing hip protectors to patients on geriatric wards is small, all scenarios showed acceptable cost-effectiveness ratios or even savings.
Authors: J Magaziner; W Hawkes; J R Hebel; S I Zimmerman; K M Fox; M Dolan; G Felsenthal; J Kenzora Journal: J Gerontol A Biol Sci Med Sci Date: 2000-09 Impact factor: 6.053
Authors: I D Cameron; S Robinovitch; S Birge; P Kannus; K Khan; J Lauritzen; J Howland; S Evans; J Minns; A Laing; P Cripton; S Derler; D Plant; D P Kiel Journal: Osteoporos Int Date: 2010-01 Impact factor: 4.507